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CELLS DETECTION IN PROSTATE CANCER PATIENTS:
A PROSPECTIVE STUDYSte´phane Moutereau, Pascal Eschwege, Zahi Aboujeili, Ste´phane
Droupy, Richard Douard, Jean-Luc Gala, Marc Conti, Philippe
Manivet, Sylvain Loric. INSERM EMI0337 and Clinical Biochemistry
and Genetics Department, APHP Mondor University Hospital, Cre´teil,
France.
Background: During the natural history of prostate cancer,
bloodstream prostate cell dissemination occurs, even in clinically
localised prostate cancer patients. Additionally, prostate manipu-
lation during radical prostatectomy induces hematogenous pros-
tatic cell dissemination. Both may play an adverse role on the
natural course of the disease. Blood-borne circulating prostate
cell detection might be helpful to better classify patients and pre-
dict recurrence.
Methods: To evaluate cancer-cell seeding impact upon patient
recurrence free survival, 111 prostate cancer patients were pro-
spectively enrolled and followed up. Prostate cell spread was
assessed by PSMA-based RT-PCR. Positive recurrence was defined
by two consecutive serum PSA values P0.2 ng/L.
Results: Forty-one patients presented blood prostate cell shed-
ding preoperatively and intraoperatively (group I). Of the 70 pre-
operatively negative patients, 38 (54%) remained negative (group
II) and 32 (46%) became intraoperatively positive (group III). Med-
ian biological and clinical recurrence-free-time was far shorter in
group I (36.2 months, p < 0.0001) than in group II (69.6 months) but
did not significantly differ in groups II and III (69.6 months versus
65.0).
Conclusions: Such 5-year follow-up data show that preoperative
circulating prostate cells are an independent prognosis factor of
recurrence. Moreover, tumor handling induces cancer-cell seed-
ing but this surgical blood dissemination does not accelerate can-
cer evolution.
doi:10.1016/j.ejcsup.2006.04.090P31. SURVIVIN mRNA LEVELS IN PERIPHERAL BLOOD
FROM PATIENTS WITH ESOPHAGEAL CANCER DECREASE
SIGNIFICANTLY FOLLOWING SURGICAL RESECTION AND
ARE INFLUENCED BY NEOADJUVANT CHEMORADIATIONA.-C. Hoffmann, U. Warnecke-Eberz, K. Prenzel, J. Brabender,
D. Vallboehmer, R. Metzger, A.H. Ho¨lscher, P.M.
Schneider. Department of Visceral and Vascular Surgery, University
of Cologne, Joseph-Stelzmann-Strasse 9, 50931 Cologne, Germany.
Background: Survivin is an inhibitor of apoptosis and specifically
expressed in several human cancers. The purpose of this study
was to evaluate if there is a difference in the level of survivin
mRNA expression between different histological types and stages
of esophageal cancer. Furthermore we evaluated if a potential
postresectional decrease in survivin mRNA expression might be
used to verify complete surgical resection and if neoadjuvant
chemoradiation would influence these results.Methods: Blood samples were obtained from 47 patients who
were scheduled for surgical resection of an esophageal carci-
noma. 21 (44.7%) patients had squamous cell carcinomas and 26
(55.3%) adenocarcinomas. In 21 (44.7%) patients neoadjuvant
chemoradiation was perforemd for locally advanced disease.
Whole blood was drawn one day preoperatively and 10 days post
resection in all patients. The tumor cells were enriched from
whole blood by density gradient centrifugation (OncoQuick,
Hexal, Frickenhausen) and total cellular RNA was extracted.
Direct quantitative real-time reverse transcriptase PCR (RT-PCR,
TaqManTM) assays were performed in triplicates to determine sur-
vivin mRNA expression levels.
Results: Survivin mRNA expression in peripheral blood was
detected in 35/47 patients (74.5%). There were no significant dif-
ferences in preoperative mRNA levels between squamous cell car-
cinomas and adenocarcinomas. Postoperative survivin levels
were significantly lower than preoperative levels in 41.2% of
resected patients. Postoperative levels were lower than preopera-
tive levels in 52.9% of patients with adenocarcinomas and 29.4%
of patients with squamous cell carcinomas. Patients who received
neoadjuvant chemoradiation had significantly lower survivin
mRNA levels postoperatively in 66.7% compared to 27.3% of
patients following primary resection (Wilcoxon test: p < 0,027).
In patients receiving neoadjuvant chemoradiation postoperative
mRNA expression levdels were detected at 83.3% of patients with
adenocarcinomas compared to only 36.4% with squamous cell
cancer.
Conclusions: Our results demonstrate that direct real-time
quantitative RT-PCR analysis of survivin mRNA expression with-
out prior nested PCR is technically feasible and reliable following
tumor cell enrichment from whole blood samples in patients with
esophageal cancer. Survivin levels were significantly reduced fol-
lowing surgical resections and might become a molecular marker
for completeness of resection (molecular R0 marker). Survivin
levels particularly decreased in adenocarcinomas following neo-
adjuvant chemoradiation and surgical resection.
doi:10.1016/j.ejcsup.2006.04.091
P32. CD133 POSITIVE ‘‘CANCER STEM CELLS’’ IN GLIOMAS OF
DIFFERENT GRADES
N. Thon, S. Grau, K. Damianoff, O. Schnell, J.C. Tonn, R.
Goldbrunner. Neurochirurgische Klinik der Universita¨t Mu¨nchen,
Germany.
Background: Within glioblastoma multiforme (GBM) specimens,
a subpopulation of CD133 positive cells with ability for self
renewal and tumor generation could be isolated suggesting the
presence of ‘‘cancer stem cells’’ (CSC) in GBM. Aim of this study
was (i) to assess the presence of CD133+ cells in gliomas grade
II, III and IV and (ii) to investigate the differentiation potential of
these cells.
Methods: Samples of WHO II (10), WHO III (10) and WHO IV (10)
gliomas were investigated immunohistochemically using the
antibody AC133/1+2, which binds to two different epitopes of
CD133, and Musashi-1, an established stem cell marker. Addition-
ally, CD133 expression was assessed by ELISA. CD133+ cells were
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n = 3) using a modified magnetic bead protocol. Differentiation
of cultured cells was assessed immunohistochemically using
anti-GFAP, -NSE, -CD31, -CD105, -VE cadherin, Musashi-1 and
AC133/1+2.
Results: CD133 positive cells could be detected in 7/10 gliomas
WHO II, 8/10 gliomas WHOIII and 9/10 GBM. These cells were
found arranged in clusters, mostly associated to intratumoral
vessels, rarely located diffusely within the tumor parenchyma.
CD133 expression correlated with WHO grade: 1–5% of cells in gli-
omas WHO II, 5–10% of cells in gliomas WHO III, and 10–15% of
cells in GBM stained positive for CD133. Western-blot analysis
confirmed the correlation with tumor grade. CD133+ cells that
have been isolated from specimens of all tumor grades stained
positive for Musashi-1. Under different culture conditions, rapid
proliferation of CD133+ cells occurred. After several passages,
cells lost CD133 expression and became positive for GFAP, NSE
or CD31/CD105/VE cadherin.
Conclusions: This study represents the first documentation for
the presence of pluripotent, highly proliferative CD133+ CSC in
low grade gliomas, which are able to differentiate into cells
expressing glial, neuronal or endothelial markers. The presence
of CSC in high grade gliomas could be confirmed, showing a
higher proportion than in low grade gliomas. The role of these
cells during stepwise glioma progression still has to be evaluated.
doi:10.1016/j.ejcsup.2006.04.092
P33. EXPRESSION OF ALPHA V BETA 3 INTEGRIN IN
PATIENTS WITH HIGH AND LOW GRADE GLIOMA
O. Schnella, B. Krebsb, E. Wagnera, A.J. Beerc, S.J. Graua, C. Goetza,
H.A. Kretzschmarb, R.H. Goldbrunnera, J.C. Tonna. aNeurochirurgische
Klinik, LMU Mu¨nchen, Germany; bZentrum fu¨r Neuropathologie und
Prionforschung, LMU Mu¨nchen, Germany; cNuklearmedizinische Klinik,
Klinikum rechts der Isar, TU Mu¨nchen, Germany.
Background: Here we show that the expression of avb3, a puta-
tive key player of angiogenesis in malignant glioma may be less
pronounced in brain derived glial tumors as supposed by former
studies and is not restricted to activated endothelial cells.
Methods: Cryosections of histopathologically confirmed high
(n = 25) and low (n = 10) grade gliomas, were immunostained for
detection of avb3-expression. Microvascular density of the sam-
ples was determined by co-staining with endothelial cell specific
markers (CD31, CD105). Moreover Western blot analysis of con-
secutive cryosections was performed to further investigate the
relative vascularisation and integrin expression in these tumors.
Results: Immunohistochemistry confirmed that high grade glio-
mas not only show a higher rate of avb3-positive proliferating
endothelial cells but have a higher number of avb3-expressing
tumor cells compared to low grade gliomas. Western blot analysis
revealed that avb3-expression in malignant gliomas was higher
as seen in low grade gliomas. Interestingly all glial tumors
showed less integrin expression and less avb3-positive endothe-
lial cells compared to solid non-CNS tumors. In return the rate
of integrin-positive tumor cells was higher in all gliomas com-
pared to the peripheral tumors.Conclusion: Expression of avb3 integrin is lower in glial tumors
compared with most peripheral solid tumors. In gliomas the frac-
tion of tumor cells expressing avb3 is higher as in non-CNS
tumors. Therefore the function of this integrin in brain derived
tumors may not be restricted to angiogenesis alone and new anti-
angiogenic drugs targeting this integrin may have control over the
tumor cells themselves.
doi:10.1016/j.ejcsup.2006.04.093
P34. EXPRESSION OF LYMPHANGIOGENSIS RELATED VEGFR3
IN MALIGNANT GLIOMAS
S. Graua, F. Trillschb, N. Thona, O. Schnella, P. Nelsonb, J.-C. Tonna,
R. Goldbrunnera. aDepartment of Neurosurgery, LMU Munich
University, Germany; bDepartment of Biochemistry, LMU Munich
University, Germany.
Background: Glioblastomas (WHO grade IV) are highly vascular-
ised brain tumours. Targeting glioma angiogenesis several studies
aim at the VEGF/VEGFR2 system, however, the presence and role
of VEGFR3 in gliomas has not been investigated elaborately up to
date. Here we show the high expression of VEGFR3 and its ligands
in gliomas correlating with tumour grade.
Method: Human brain tumours WHO grade II (n = 8), grade IV
(n = 20) and non neoplastic brain (n = 3) were investigated for
expression of VEGFR-3, VEGF-C and VEGF-D on mRNA and protein
level by use of real-time PCR, immunohistochemistry and Wes-
tern blot analysis.
Results: Expression of VEGFR-3, VEGF-C and VEGF-D was very
high in glioblastomas, scant in grade II gliomas and absent in
non neoplastic brain. These findings were confirmed by Western
blot. VEGFR-3 in glioblastomas was mainly present on tumor
endothelium. VEGF-C and -D were expressed strongest in areas
of high vessel density. On mRNA level, transcripts for all proteins
were significantly elevated in glioblastomas compared to grade II
gliomas and non neoplastic brain.
Conclusion: VEGFR3 expression correlates with tumour grade
showing highest levels in glioblastomas. With also the receptor
ligands VEGF-C and -D being strongly expressed, these findings
reveal the presence of an alternative angiogenic signalling system
in these tumours. This may influence the paradigm of glioma
angiogenesis and may lead to more effective anti-angiogenic
treatment strategies.
doi:10.1016/j.ejcsup.2006.04.094
P35. INTRATUMORAL PATTERNS OF CLONAL EVOLUTION
IN MENINGIOMAS
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